GB201006166D0 - Compounds for the treatment of metabolic disorders - Google Patents
Compounds for the treatment of metabolic disordersInfo
- Publication number
- GB201006166D0 GB201006166D0 GBGB1006166.1A GB201006166A GB201006166D0 GB 201006166 D0 GB201006166 D0 GB 201006166D0 GB 201006166 A GB201006166 A GB 201006166A GB 201006166 D0 GB201006166 D0 GB 201006166D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- compounds
- treatment
- metabolic disorders
- metabolic
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1006166.1A GB201006166D0 (en) | 2010-04-14 | 2010-04-14 | Compounds for the treatment of metabolic disorders |
| PCT/EP2011/055864 WO2011128394A1 (en) | 2010-04-14 | 2011-04-13 | 3-substituted 5-(pyrrolidine-1-carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1006166.1A GB201006166D0 (en) | 2010-04-14 | 2010-04-14 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201006166D0 true GB201006166D0 (en) | 2010-05-26 |
Family
ID=42236248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1006166.1A Ceased GB201006166D0 (en) | 2010-04-14 | 2010-04-14 | Compounds for the treatment of metabolic disorders |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201006166D0 (en) |
| WO (1) | WO2011128394A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY160300A (en) * | 2010-10-14 | 2017-02-28 | Daiichi Sankyo Co Ltd | Acylbenzene derivative |
| EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| JP2015522080A (en) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| EP1930319B1 (en) * | 2000-08-10 | 2012-05-02 | Mitsubishi Tanabe Pharma Corporation | Proline derivatives and use thereof as drugs |
| JP4383177B2 (en) | 2002-03-01 | 2009-12-16 | スミスクライン ビーチャム コーポレーション | hPPAR activator |
| AU2004303604B2 (en) | 2003-12-24 | 2011-03-24 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
| US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
| CA2591922A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Limited | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| MX2007016508A (en) | 2005-06-30 | 2008-03-04 | Prosidion Ltd | Gpcr agonists. |
| US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| BRPI0612599A2 (en) | 2005-06-30 | 2010-11-23 | Prosidion Ltd | compound, pharmaceutical composition comprising the same, method of treatment and use thereof |
| CA2646676A1 (en) | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
| GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| HRP20110852T1 (en) | 2007-01-04 | 2011-12-31 | Prosidion Limited | Piperidine gpcr agonists |
| CL2008000018A1 (en) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE |
| PE20081849A1 (en) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | PIPERIDIN-4-IL-PROPOXY-BENZAMIDE DERIVATIVES AS GPCR AGONISTS |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| JP2010514832A (en) | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | Piperidine GPCR agonist |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| WO2008157330A1 (en) | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
| CA2693169C (en) | 2007-07-19 | 2016-01-12 | Metabolex, Inc. | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
| US20100286112A1 (en) | 2007-09-10 | 2010-11-11 | Oscar Barba | Compounds for the treatment of metabolic disorders |
| US8568899B2 (en) | 2007-10-18 | 2013-10-29 | Jx Nippon Mining & Metals Corporation | Metal covered polyimide composite, process for producing the composite, and process for producing electronic circuit board |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| EP2280704B1 (en) * | 2008-03-31 | 2015-05-13 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds and uses thereof |
| GB0812031D0 (en) | 2008-07-01 | 2008-08-06 | 7Tm Pharma As | Thiazole derivatives |
| GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| ATE557024T1 (en) | 2008-07-10 | 2012-05-15 | Prosidion Ltd | PIPERIDINE COMPOUNDS AS GPCR AGONISTS |
| GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| AU2009269772A1 (en) | 2008-07-10 | 2010-01-14 | Prosidion Limited | Piperidinyl GPCR agonists |
-
2010
- 2010-04-14 GB GBGB1006166.1A patent/GB201006166D0/en not_active Ceased
-
2011
- 2011-04-13 WO PCT/EP2011/055864 patent/WO2011128394A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011128394A1 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| KR102297388B9 (en) | Use of akkermansia for treating metabolic disorders | |
| GB0904285D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| GB2503852B (en) | Compounds for the treatment of neuropsychiatric disorders | |
| ZA201107446B (en) | Compounds for the treatment of metabolic disorders | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| GB0904284D0 (en) | Compounds for the treatment of metabolic disorders | |
| IL225896A0 (en) | Treatment of mecp2-associated disorders | |
| IL235058A0 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| BR112013015048A2 (en) | composition for the treatment of metabolic disorders | |
| PL2882724T3 (en) | Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac | |
| GB201006167D0 (en) | Compounds for the treatment of metabolic disorders | |
| IL234616A0 (en) | Herbal composition for the treatment of metabolic disorders | |
| GB201006166D0 (en) | Compounds for the treatment of metabolic disorders | |
| IL234796B (en) | Compounds for the treatment of ischemia-reperfusion-related diseases | |
| EP2240024A4 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004742D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004741D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004740D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201019482D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201006164D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201006163D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004744D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201106154D0 (en) | Compounds for the treatment of metabolic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |